A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

Trial Profile

A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Inebilizumab (Primary)
  • Indications Neuromyelitis optica
  • Focus Registrational; Therapeutic Use
  • Acronyms N-MOmentum
  • Sponsors MedImmune
  • Most Recent Events

    • 02 Aug 2017 Planned End Date changed from 26 Jul 2021 to 10 May 2023.
    • 02 Aug 2017 Planned primary completion date changed from 29 Jul 2019 to 15 May 2019.
    • 09 May 2017 Planned number of patients changed from 212 to 252.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top